Preferred Label : Entrectinib;
NCIt synonyms : N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;
NCIt definition : An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases
(Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with
potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits
TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption
of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction
of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express
these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer
cell types.;
UNII : L5ORF0AN1I;
InChIKey : HAYYBYPASCDWEQ-UHFFFAOYSA-N;
CAS number : 1108743-60-7;
Drug name : Rozlytrek;
Molecule name : RXDX-101; RXDX 101;
Codes from synonyms : 188;
Origin ID : C114984;
UMLS CUI : C4086264;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
